What happened
A comprehensive review in Current Molecular Pharmacology (2026, Volume 19, Pages 85-96) surveys computational tools for predicting tumour drug resistance, per News-Medical. The paper is led by Jia Wang, Hong-Rui Zhu, with corresponding authors Zhi-Chun Gu and Hou-Wen Lin from Shanghai Jiao Tong University School of Medicine, News-Medical reports. The review documents uses of machine learning and deep learning to integrate multi-omics and clinical data from large repositories including TCGA and GDSC to study resistance mechanisms in chemotherapy, targeted therapy, and immunotherapy, News-Medical writes.
Technical details
Per the review as summarised by News-Medical, authors emphasise preprocessing and data-standardisation pipelines to convert heterogeneous genomic, transcriptomic, and clinical records into reliable model inputs. The review highlights common technical barriers reported in the literature: data sparsity, batch effects, and the opaque or "black-box" behavior of many deep-learning architectures. The article explicitly recommends frameworks for explainable AI, multimodal fusion strategies, and integrating dynamic liquid monitoring to track resistance evolution in longitudinal samples, News-Medical reports. The piece contains direct quotes: "The inherent trade-off between model accuracy and interpretability undermines clinician trust and limits real-world adoption," says Dr. Zhi-Chun Gu, and "Our goal is to move beyond generic predictions and deliver tailored insights for the patients who need them most," says Professor Hou-Wen Lin, according to News-Medical.
Industry context
Editorial analysis: Reviews that synthesise multi-omics modelling and clinical constraints help crystallise where engineering effort is most needed, notably data harmonisation, explainability, and prospective validation. Companies and academic groups building clinical ML pipelines commonly face the same technical frictions the review lists: inconsistent ontologies across cohorts, limited labelled progression events, and regulatory expectations for interpretability.
Implications for practitioners
Editorial analysis: For ML engineers and translational researchers, the review reinforces practical priorities: invest early in standardized data schemas, adopt interpretable model families or post hoc explanation techniques, and design prospective studies that capture longitudinal biomarkers such as circulating tumour DNA or coagulation markers if targeting thrombotic subgroups.
What to watch
Editorial analysis: Observers should track emergence of community standards for cancer clinical-omics, publications reporting prospective validation of resistance predictors, and toolkits that operationalise multimodal fusion with explainability baked in. The review's call for specialised models for patients with cancer-associated thrombosis is a specific research direction to monitor, per News-Medical.
Key Points
- 1Review in Current Molecular Pharmacology synthesises ML/deep learning uses for predicting tumour drug resistance from multi-omics and clinical data.
- 2Authors highlight data-standardisation, preprocessing, and explainability as prerequisites for clinical translation, reflecting common technical bottlenecks.
- 3Industry observers should prioritise prospective validation, longitudinal liquid-biopsy integration, and standardised data schemas to move models toward real-world use.
Scoring Rationale
A field-level review consolidates methods and barriers that matter to practitioners building translational ML for oncology. It is notable for setting technical priorities but does not present a new model or prospective clinical results.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
